- Home
- IMUX vs SFWL Comparison
IMUX vs SFWL Comparison
Compare IMUX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- SFWL
- Stock Information
- Founded
- IMUX 2016
- SFWL 2001
- Country
- IMUX United States
- SFWL China
- Employees
- IMUX N/A
- SFWL N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- SFWL Trucking Freight/Courier Services
- Sector
- IMUX Health Care
- SFWL Industrials
- Exchange
- IMUX Nasdaq
- SFWL Nasdaq
- Market Cap
- IMUX 67.8M
- SFWL 81.0M
- IPO Year
- IMUX N/A
- SFWL 2023
- Fundamental
- Price
- IMUX $0.73
- SFWL $0.95
- Analyst Decision
- IMUX Strong Buy
- SFWL
- Analyst Count
- IMUX 6
- SFWL 0
- Target Price
- IMUX $11.60
- SFWL N/A
- AVG Volume (30 Days)
- IMUX 2.5M
- SFWL 10.7K
- Earning Date
- IMUX 08-07-2025
- SFWL 07-15-2025
- Dividend Yield
- IMUX N/A
- SFWL N/A
- EPS Growth
- IMUX N/A
- SFWL 4.79
- EPS
- IMUX N/A
- SFWL 0.13
- Revenue
- IMUX N/A
- SFWL $504,158,000.00
- Revenue This Year
- IMUX N/A
- SFWL N/A
- Revenue Next Year
- IMUX N/A
- SFWL N/A
- P/E Ratio
- IMUX N/A
- SFWL $7.22
- Revenue Growth
- IMUX N/A
- SFWL 24.75
- 52 Week Low
- IMUX $0.56
- SFWL $0.86
- 52 Week High
- IMUX $2.11
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- IMUX 41.54
- SFWL 56.44
- Support Level
- IMUX $0.68
- SFWL $0.95
- Resistance Level
- IMUX $0.74
- SFWL $1.02
- Average True Range (ATR)
- IMUX 0.06
- SFWL 0.05
- MACD
- IMUX 0.00
- SFWL 0.00
- Stochastic Oscillator
- IMUX 27.43
- SFWL 100.00
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.